In conclusion, ARX788, a site-specific homogeneous ADC, demonstrated intracranial efficacy for active BrMs in HER2-positive breast cancer patients previously treated with trastuzumab, taxanes, and TKI-containing treatments. This evidence concerns the gene ERBB2 and breast carcinoma.